• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis.

作者信息

Penkert Horst, Delbridge Claire, Wantia Nina, Wiestler Benedikt, Korn Thomas

机构信息

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Division of Neuropathology, Institute of Pathology, Technische Universität München, Munich, Germany.

出版信息

JAMA Neurol. 2016 Jun 1;73(6):757-9. doi: 10.1001/jamaneurol.2016.0146.

DOI:10.1001/jamaneurol.2016.0146
PMID:27043129
Abstract
摘要

相似文献

1
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis.一名接受阿仑单抗治疗复发缓解型多发性硬化症的患者发生暴发性中枢神经系统诺卡菌病
JAMA Neurol. 2016 Jun 1;73(6):757-9. doi: 10.1001/jamaneurol.2016.0146.
2
Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient.一名青少年患者在接受阿仑单抗挽救治疗后，肿胀型复发缓解型多发性硬化症实现长期缓解。
Mult Scler Relat Disord. 2020 Jun;41:102061. doi: 10.1016/j.msard.2020.102061. Epub 2020 Mar 16.
3
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.在接受芬戈莫德治疗的 50 例复发缓解型多发性硬化症患者中，阿仑单抗作为突破性疾病的挽救治疗：一项多中心观察性研究。
J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.
4
Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.阿仑单抗治疗复发缓解型多发性硬化症后发生的急性后部多灶性鳞状色素上皮病变
J Neurol. 2019 Jun;266(6):1539-1540. doi: 10.1007/s00415-019-09288-y. Epub 2019 Mar 20.
5
Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.肺北京诺卡菌感染与多发性硬化症患者使用阿仑单抗有关。
Mult Scler. 2017 May;23(6):872-874. doi: 10.1177/1352458517694431. Epub 2017 Feb 1.
6
Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.克拉屈滨治疗复发缓解型多发性硬化后播散性诺卡菌病：一例报告
J Neurol. 2022 Aug;269(8):4557-4559. doi: 10.1007/s00415-022-11097-9. Epub 2022 Mar 30.
7
Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.阿仑单抗作为那他珠单抗停药后多发性硬化症复发的挽救性治疗：临床病例及文献复习。
Mult Scler Relat Disord. 2019 May;30:262-264. doi: 10.1016/j.msard.2019.03.002. Epub 2019 Mar 5.
8
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.COVID-19 与多发性硬化症：两例阿仑单抗治疗病例描述。
Mult Scler Relat Disord. 2020 Oct;45:102402. doi: 10.1016/j.msard.2020.102402. Epub 2020 Jul 17.
9
Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.在复发型多发性硬化症患者中，阿仑单抗治疗后调节性 B 细胞缺陷的恢复。
J Neuroinflammation. 2018 Oct 30;15(1):300. doi: 10.1186/s12974-018-1334-y.
10
Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.利斯特氏菌性脑膜脑炎导致的死亡率在复发缓解型多发性硬化症患者接受阿仑单抗治疗后升高。
Mult Scler Relat Disord. 2018 Aug;24:38-41. doi: 10.1016/j.msard.2018.05.014. Epub 2018 May 18.

引用本文的文献

1
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.高效多发性硬化症疗法对B细胞的影响。
Cells. 2025 Apr 17;14(8):606. doi: 10.3390/cells14080606.
2
Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.克拉屈滨治疗复发缓解型多发性硬化后播散性诺卡菌病：一例报告
J Neurol. 2022 Aug;269(8):4557-4559. doi: 10.1007/s00415-022-11097-9. Epub 2022 Mar 30.
3
Surgery and antibiotics for the treatment of lupus nephritis with cerebral abscesses: A case report.手术及抗生素治疗狼疮性肾炎合并脑脓肿：一例报告
World J Clin Cases. 2022 Feb 26;10(6):1981-1990. doi: 10.12998/wjcc.v10.i6.1981.
4
Infection in Nephrotic Syndrome Patients: Three Case Studies and A Systematic Literature Review.肾病综合征患者的感染：三个病例研究和系统文献回顾。
Front Cell Infect Microbiol. 2022 Jan 24;11:789754. doi: 10.3389/fcimb.2021.789754. eCollection 2021.
5
Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk.用治疗性抗体治疗自身免疫性疾病：从原发性免疫缺陷病患者身上吸取的经验有助于对感染风险进行分层。
Methods Mol Biol. 2022;2313:27-44. doi: 10.1007/978-1-0716-1450-1_2.
6
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.阿仑单抗6年的疗效与安全性：4年CARE-MS扩展试验的最终结果
Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134. doi: 10.1177/1756286420982134. eCollection 2021.
7
Monoclonal Antibodies as Neurological Therapeutics.单克隆抗体作为神经学治疗药物
Pharmaceuticals (Basel). 2021 Jan 26;14(2):92. doi: 10.3390/ph14020092.
8
Isolated Nocardiosis, an Unrecognized Primary Immunodeficiency?孤立性奴卡菌病，一种未被认识的原发性免疫缺陷病？
Front Immunol. 2020 Oct 20;11:590239. doi: 10.3389/fimmu.2020.590239. eCollection 2020.
9
The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective.阿仑单抗在复发缓解型多发性硬化症患者中的应用：海湾地区的观点。
Ther Adv Neurol Disord. 2020 Sep 16;13:1756286420954119. doi: 10.1177/1756286420954119. eCollection 2020.
10
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.生物制剂和小分子靶向免疫调节治疗的感染并发症。
Clin Microbiol Rev. 2020 Jun 10;33(3). doi: 10.1128/CMR.00035-19. Print 2020 Jun 17.